RxDoctor Payments Data

Megan Erbes

Family · Goodyear, AZNPI 1558933432

Payments from drug & device makers

$5,996in general payments, 2019–2025

Across 339 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$926
  • AstraZeneca$733
  • Astellas Pharma US Inc$587
  • GSK$444
  • Boehringer Ingelheim$401
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$5,83497%
  • Education$1623%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,996 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$39,020
Medicare patients
164
Services billed
707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$59,695
FarxigaDapagliflozin Propanediol48$58,136
RybelsusSemaglutide11$20,331
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$16,855
EliquisApixaban20$16,430
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$11,698
Albuterol Sulfate HfaAlbuterol Sulfate117$2,658
Rosuvastatin Calcium50$1,496
Atorvastatin Calcium145$1,138
Levothyroxine Sodium124$1,035
Colchicine11$979
Oxybutynin Chloride ErOxybutynin Chloride22$927
Gabapentin61$861
Bupropion XlBupropion Hcl25$851
Pantoprazole Sodium46$808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,226$80,02656 claims
AstraZenecaFarxiga, Breztri Aerosphere$733$74,99164 claims
PfizerEliquis$103$16,43020 claims
AbbVieArmour Thyroid$926$45919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.

Other family in Goodyear

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →